Pharmaceutical company · RHHBY

Roche
clinical trial
pipeline

Registry checked

Published

Afimkibart is linked to 14 distinct active studies: 8 recruiting, 6 active but not recruiting. Ocrelizumab is linked to 14 distinct active studies: 3 recruiting, 10 active but not recruiting, 1 not yet recruiting. Atezolizumab is linked to 13 distinct active studies: 1 recruiting, 12 active but not recruiting.

26 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

257active trials
as lead sponsor
  • Phase 155
  • Phase 279
  • Phase 395
  • Phase 49
  • Phase not recorded19

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

6140 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved earlier by 4 days

2026-10-20 (estimated)2026-10-16 (actual)
20 Oct 202616 Oct 2026

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048 · ClinicalTrials.gov
Recorded by ComplyRx
28 Oct 2026
Registry last updated
27 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-011210153
2026-10-020000332
2026-10-032200263
2026-10-040000000
2026-10-050000000
2026-10-060100011
2026-10-071000011
2026-10-083110054
2026-10-090100011
2026-10-101000122
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-151200364
2026-10-161000232
2026-10-170000221
2026-10-180000000
2026-10-190000000
2026-10-202110042
2026-10-211000011
2026-10-223110053
2026-10-230101022
2026-10-241120152
2026-10-250000000
2026-10-260000000
2026-10-273000033
2026-10-280100122
2026-10-291010241
2026-10-300000000
Type totals211471186140 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Ocrelizumab

ocrevus

14
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 23
  • Phase 37
  • Phase 42
  • Phase not recorded1
Studied condition
Multiple Sclerosis · Multiple Sclerosis, Primary Progressive · Primary Progressive Multiple Sclerosis
Next primary completion
Not reported
Open drug

Afimkibart

Canonical investigational asset

14
Active trials
8
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 25
  • Phase 37
  • Phase 40
  • Phase not recorded0
Studied condition
Active Ulcerative Colitis · Atopic Dermatitis · Crohns Disease
Next primary completion
31 December 2026 · estimated
Open drug

Atezolizumab

Tecentriq

13
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 310
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Liver Cancers · Breast Cancer · Cancer
Next primary completion
30 November 2026 · estimated
Open drug

Inavolisib

itovebi

12
Active trials
9
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 13
  • Phase 25
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Breast Cancer · Diabetes Type II · Metastatic Breast Cancer
Next primary completion
13 November 2026 · estimated
Open drug

Cevostamab

Canonical investigational asset

9
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 15
  • Phase 23
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Lupus Erythematosus, Systemic · Multiple Myeloma · Relapsed or Refractory Multiple Myeloma
Next primary completion
26 February 2027 · estimated
Open drug

Giredestrant

Canonical investigational asset

9
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 22
  • Phase 36
  • Phase 40
  • Phase not recorded0
Studied condition
Breast Cancer · Early Breast Cancer · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Next primary completion
Not reported
Open drug

226 of 257 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 226 of 257 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Roche trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
BRAVE
Venetoclax

NCT06524375

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 09 Aug 2024 · actual
    Primary completion: 31 Oct 2026 · estimated
    Study completion: 31 Jan 2030 · estimated

    2021202220232024202520262027202820292030
    INAVO121
    Inavolisib

    NCT05646862

    Phase 3 · Recruiting

    Trial source and qualifications

    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

    5 candidate observations · 1 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    4 inspected observations omitted. At most three verified observations are shown, not full history.

    • status flip · Recorded 2026-09-01 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 07 Jun 2023 · actual
    Primary completion: 13 Nov 2026 · estimated
    Study completion: 30 Mar 2029 · estimated

    2021202220232024202520262027202820292030
    SHIELD DMD
    Satralizumab

    NCT06450639

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 6 inspected observations were not displayed.

    7 candidate observations · 1 shown · 0 recorded after primary completion · 6 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    6 inspected observations omitted. At most three verified observations are shown, not full history.

    • pc date moved · Recorded 2026-09-04 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 04 Apr 2025 · actual
    Primary completion: 18 Nov 2026 · estimated
    Study completion: 18 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
    RO7269162

    NCT06402838

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

    5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    5 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 02 May 2024 · actual
      Primary completion: 19 Nov 2026 · estimated
      Study completion: 19 Nov 2026 · estimated

      2021202220232024202520262027202820292030
      A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
      Atezolizumab

      NCT03148418

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

      Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      Start clipped at the display horizon.

      2 candidate observations · 1 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

      • pc date moved · Recorded 2026-10-09 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 20 Sept 2017 · actual
      Primary completion: 30 Nov 2026 · estimated
      Study completion: 30 Nov 2026 · estimated

      2021202220232024202520262027202820292030
      NAUTIKA1
      Alectinib

      NCT04302025

      Phase 2 · Recruiting

      Trial source and qualifications

      A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

      Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      Start clipped at the display horizon.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 06 Nov 2020 · actual
        Primary completion: 30 Nov 2026 · estimated
        Study completion: 30 May 2030 · estimated

        2021202220232024202520262027202820292030

        Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

        6 selected of 105 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 44 actual primary completions, 0 untyped primary completions, 8 past estimates, 17 outside the horizon, 0 contradictory dates.

        04 / Therapeutic focus

        Where the activity is

        110

        active trials in Oncology

        Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

        Active trials by primary therapeutic area

        • Oncology110 trials
        • Neurology42 trials
        • Immunology & Inflammation21 trials
        • Metabolic/Endocrine/Nutrition17 trials
        • Ophthalmology14 trials
        • Haematology10 trials
        • Renal & Urology3 trials
        • Cardiovascular2 trials
        • Dermatology2 trials
        • Gastroenterology & Hepatology2 trials
        • Infectious Disease2 trials
        • Respiratory2 trials
        • Unmapped26 trials
        • Healthy volunteers4 trials

        Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

        06 / Related companies

        All companies
        B

        Bayer

        Shared indexed programme context · 1 selected asset

        S

        Sandoz

        Shared indexed programme context · 1 selected asset

        Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

        Sources, scope and methodology

        ClinicalTrials.gov lead-sponsor scope

        Canonical current-owner attribution covers 2,709 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Roche. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

        ClinicalTrials.gov

        Attribution coverage

        2,709 distinct registry candidates produced 2,709 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

        Indexed enrichment

        2,288 scoped records have indexed enrichment and 421 do not. Missing enrichment does not remove a trial from cohort counts.

        Scope observation

        The successful attribution check completed at 2026-10-31T23:01:05.807Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 0286750433931abaffd7d024dd491d3d549448e477629c6c200366c6e882488b.

        Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

        Dated canonical-attribution snapshot: 2,709 mapped lead-sponsored clinical studies across all statuses. 2,288 have indexed enrichment, 421 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

        Keep following
        what matters.

        Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

        Build your watch

        Choose what to track in the watch builder.